Sangamo Total Liab vs Total Current Assets Analysis
SGMO Stock | USD 0.57 0.02 3.64% |
Sangamo Therapeutics financial indicator trend analysis is much more than just breaking down Sangamo Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sangamo Therapeutics is a good investment. Please check the relationship between Sangamo Therapeutics Total Liab and its Total Current Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
Total Liab vs Total Current Assets
Total Liab vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sangamo Therapeutics Total Liab account and Total Current Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Sangamo Therapeutics' Total Liab and Total Current Assets is 0.92. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Sangamo Therapeutics, assuming nothing else is changed. The correlation between historical values of Sangamo Therapeutics' Total Liab and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Sangamo Therapeutics are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Liab i.e., Sangamo Therapeutics' Total Liab and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.92 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Sangamo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.As of the 15th of May 2024, Selling General Administrative is likely to grow to about 64.2 M, though Tax Provision is likely to grow to (4.3 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 110.7M | 111.3M | 154.0M | 161.7M | Total Revenue | 110.7M | 111.3M | 176.2M | 185.0M |
Sangamo Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Sangamo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sangamo Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 637.5M | 938.6M | 721.9M | 562.5M | 165.3M | 218.1M | |
Total Stockholder Equity | 432.7M | 497.4M | 375.3M | 295.0M | 82.9M | 144.6M | |
Retained Earnings | (657.0M) | (778.0M) | (956.3M) | (1.1B) | (1.4B) | (1.3B) | |
Other Assets | 10.6M | 15.1M | 16.8M | 18.5M | 1.0 | 0.95 | |
Common Stock Shares Outstanding | 112.1M | 134.4M | 144.6M | 154.3M | 174.4M | 183.2M | |
Liabilities And Stockholders Equity | 637.5M | 938.6M | 721.9M | 562.5M | 165.3M | 218.1M | |
Other Stockholder Equity | 1.1B | 1.3B | 1.3B | 1.5B | 1.5B | 1.6B | |
Total Liab | 204.8M | 441.2M | 346.6M | 267.6M | 82.4M | 73.5M | |
Short Long Term Debt Total | 44.4M | 42.1M | 48.1M | 43.1M | 38.1M | 30.0M | |
Other Current Liab | 21.3M | 30.7M | 28.4M | 33.4M | 27.9M | 29.3M | |
Total Current Liabilities | 69.9M | 143.5M | 127.9M | 111.7M | 47.7M | 34.0M | |
Property Plant And Equipment Net | 107.2M | 112.4M | 124.7M | 125.5M | 52.9M | 29.2M | |
Accounts Payable | 6.7M | 12.6M | 9.8M | 22.4M | 15.3M | 16.0M | |
Cash | 80.4M | 131.3M | 178.9M | 100.4M | 45.2M | 45.0M | |
Non Current Assets Total | 232.0M | 278.9M | 323.2M | 262.2M | 71.0M | 68.1M | |
Non Currrent Assets Other | 4.0M | 7.9M | 10.2M | 12.3M | 16.6M | 17.5M | |
Cash And Short Term Investments | 385.0M | 692.0M | 464.7M | 277.6M | 81.0M | 77.0M | |
Net Receivables | 37.6M | 6.3M | 6.4M | 4.5M | 1.3M | 1.3M | |
Common Stock Total Equity | 1.2M | 1.4M | 1.5M | 1.7M | 1.5M | 1.4M | |
Short Term Investments | 282.0M | 510.1M | 197.7M | 177.2M | 35.8M | 34.0M | |
Non Current Liabilities Total | 134.9M | 297.6M | 218.7M | 155.8M | 34.7M | 57.7M | |
Property Plant And Equipment Gross | 107.2M | 112.4M | 149.7M | 162.1M | 103.9M | 109.1M | |
Total Current Assets | 405.5M | 659.7M | 398.8M | 300.3M | 94.3M | 175.7M | |
Accumulated Other Comprehensive Income | (2.4M) | 5.4M | (4.0M) | (8.4M) | (4.6M) | (4.4M) | |
Common Stock | 1.2M | 1.4M | 1.5M | 1.7M | 1.8M | 1.7M | |
Net Debt | (36.0M) | (89.2M) | (130.8M) | (57.3M) | (7.1M) | (7.5M) | |
Other Current Assets | 5.4M | 12.0M | 15.9M | 18.2M | 12M | 12.6M | |
Property Plant Equipment | 29.9M | 41.3M | 51.5M | 63.5M | 73.1M | 76.7M | |
Current Deferred Revenue | 38.7M | 96.6M | 85.7M | 51.8M | 59.5M | 62.5M | |
Intangible Assets | 53.2M | 58.1M | 53.8M | 50.7M | 58.3M | 61.3M | |
Other Liab | 93.7M | 259.2M | 174.6M | 116.9M | 134.4M | 141.1M | |
Net Tangible Assets | 340.1M | 397.3M | 281.9M | 206.7M | 237.7M | 227.0M | |
Retained Earnings Total Equity | (657.0M) | (778.0M) | (956.3M) | (1.1B) | (1.0B) | (982.0M) | |
Capital Surpluse | 1.1B | 1.3B | 1.3B | 1.5B | 1.7B | 873.1M | |
Inventory | (22.5M) | (50.5M) | (88.2M) | 1.0 | 0.9 | 0.95 | |
Deferred Long Term Liab | 6.6M | 7.2M | 6.6M | 6.3M | 7.2M | 9.3M |
Currently Active Assets on Macroaxis
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Transaction History View history of all your transactions and understand their impact on performance | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.88) | Revenue Per Share 0.106 | Quarterly Revenue Growth (1.00) | Return On Assets (0.49) | Return On Equity (1.67) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.